TY - JOUR
T1 - The Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value-Added Medicines
T2 - As-Needed Treatment in Allergic Rhinitis
AU - Bousquet, Jean
AU - Toumi, Mondher
AU - Sousa-Pinto, Bernardo
AU - Anto, Josep M.
AU - Bedbrook, Anna
AU - Czarlewski, Wienczyslawa
AU - Valiulis, Arunas
AU - Ansotegui, Ignacio J.
AU - Bosnic-Anticevich, Sinthia
AU - Brussino, Luisa
AU - Canonica, G. Walter
AU - Cecchi, Lorenzo
AU - Cherrez-Ojeda, Ivan
AU - Chivato, Tomas
AU - Costa, Elísio M.
AU - Cruz, Alvaro A.
AU - Del Giacco, Stefano
AU - Fonseca, Joao A.
AU - Gemicioglu, Bilun
AU - Haahtela, Tari
AU - Ivancevich, Juan Carlos
AU - Jutel, Marek
AU - Kaidashev, Igor
AU - Klimek, Ludger
AU - Kvedariene, Violeta
AU - Kuna, Piotr
AU - Larenas-Linnemann, Désirée E.
AU - Lipworth, Brian
AU - Morais-Almeida, Mario
AU - Mullol, Joaquim
AU - Papadopoulos, Nikolaos G.
AU - Patella, Vincenzo
AU - Pham-Thi, Nhân
AU - Regateiro, Frederico S.
AU - Rouadi, Philip W.
AU - Samolinski, Boleslaw
AU - Sheikh, Aziz
AU - Taborda-Barata, Luis
AU - Ventura, Maria Teresa
AU - Yorgancioglu, Arzu
AU - Zidarn, Mihaela
AU - Zuberbier, Torsten
N1 - Publisher Copyright:
© 2022 American Academy of Allergy, Asthma & Immunology
PY - 2022/11
Y1 - 2022/11
N2 - Drug repurposing is a major field of value-added medicine. It involves investigating and evaluating existing drugs for new therapeutic purposes that address unmet healthcare needs. Several unmet needs in allergic rhinitis could be improved by drug repurposing. This could be game-changing for disease management. Current medications for allergic rhinitis are centered on continuous long-term treatment, and medication registration is based on randomized controlled trials carried out for a minimum of 14 days with adherence of 70% or greater. A new way of treating allergic rhinitis is to propose as-needed treatment depending on symptoms, rather than classical continuous treatment. This rostrum will discuss existing clinical trials on as-needed treatment for allergic rhinitis and real-world data obtained by the mobile health app MASK-air, which focuses on digitally-enabled, patient-centered care pathways.
AB - Drug repurposing is a major field of value-added medicine. It involves investigating and evaluating existing drugs for new therapeutic purposes that address unmet healthcare needs. Several unmet needs in allergic rhinitis could be improved by drug repurposing. This could be game-changing for disease management. Current medications for allergic rhinitis are centered on continuous long-term treatment, and medication registration is based on randomized controlled trials carried out for a minimum of 14 days with adherence of 70% or greater. A new way of treating allergic rhinitis is to propose as-needed treatment depending on symptoms, rather than classical continuous treatment. This rostrum will discuss existing clinical trials on as-needed treatment for allergic rhinitis and real-world data obtained by the mobile health app MASK-air, which focuses on digitally-enabled, patient-centered care pathways.
KW - Allergic rhinitis
KW - MASK-air
KW - Repurposing
KW - Treatment
KW - Value-added medicine
UR - https://www.scopus.com/pages/publications/85138811635
U2 - 10.1016/j.jaip.2022.07.020
DO - 10.1016/j.jaip.2022.07.020
M3 - Artículo
C2 - 35934308
AN - SCOPUS:85138811635
SN - 2213-2198
VL - 10
SP - 2878
EP - 2888
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 11
ER -